Is SNTI or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media refer more to SNTI or ALDX?

In the previous week, Senti Biosciences had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 1 mentions for Aldeyra Therapeutics. Senti Biosciences' average media sentiment score of 0.23 beat Aldeyra Therapeutics' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SNTI or PMN more profitable?

Promis Neurosciences' return on equity of -237.99% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Promis Neurosciences N/A -237.99% -151.04%

Does the media favor SNTI or PMN?

In the previous week, Senti Biosciences had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Senti Biosciences and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.32 beat Senti Biosciences' score of 0.23 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SNTI or LIXT?

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 2,014.16%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Senti Biosciences is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or LIXT more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Lixte Biotechnology N/A -134.91% -95.61%

Does the media favor SNTI or LIXT?

In the previous week, Senti Biosciences had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Senti Biosciences and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.84 beat Senti Biosciences' score of 0.23 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SNTI or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Enlivex Therapeutics N/A 248.08% 206.39%

Does the media prefer SNTI or ENLV?

In the previous week, Senti Biosciences had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat Senti Biosciences' score of 0.23 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Senti Biosciences (SNTI) Competitors

$0.47 +0.04 (+9.04%)

As of 11:04 AM Eastern

Compare

SNTI vs. ALDX, PMN, COYA, LIXT, and ENLV

Should you buy Senti Biosciences stock or one of its competitors? MarketBeat compares Senti Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Senti Biosciences include Aldeyra Therapeutics (ALDX), Promis Neurosciences (PMN), Coya Therapeutics (COYA), Lixte Biotechnology (LIXT), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry.

How does Senti Biosciences compare to Aldeyra Therapeutics?

Senti Biosciences (NASDAQ:SNTI) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Senti Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 2,014.16%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 217.92%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Senti Biosciences is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics' return on equity of -57.34% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

In the previous week, Senti Biosciences had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 1 mentions for Aldeyra Therapeutics. Senti Biosciences' average media sentiment score of 0.23 beat Aldeyra Therapeutics' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Senti Biosciences has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Aldeyra Therapeutics has lower revenue, but higher earnings than Senti Biosciences. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	736.70	-$61.44M	-$1.92	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Senti Biosciences beats Aldeyra Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Promis Neurosciences?

Senti Biosciences (NASDAQ:SNTI) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

In the previous week, Senti Biosciences had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Senti Biosciences and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.32 beat Senti Biosciences' score of 0.23 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 2,014.16%. Promis Neurosciences has a consensus target price of $24.00, indicating a potential upside of 64.27%. Given Senti Biosciences' higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Promis Neurosciences has lower revenue, but higher earnings than Senti Biosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	736.70	-$61.44M	-$1.92	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Senti Biosciences has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Promis Neurosciences' return on equity of -237.99% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Promis Neurosciences	N/A	-237.99%	-151.04%

Summary

Senti Biosciences beats Promis Neurosciences on 8 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Coya Therapeutics?

Senti Biosciences (NASDAQ:SNTI) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Coya Therapeutics has higher revenue and earnings than Senti Biosciences. Coya Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	736.70	-$61.44M	-$1.92	N/A
Coya Therapeutics	$7.95M	13.34	-$21.23M	-$1.15	N/A

Senti Biosciences has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Senti Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 2,014.16%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 239.23%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Senti Biosciences had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 0 mentions for Coya Therapeutics. Senti Biosciences' average media sentiment score of 0.23 beat Coya Therapeutics' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Neutral
Coya Therapeutics	Neutral

Senti Biosciences has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Summary

Senti Biosciences beats Coya Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Senti Biosciences compare to Lixte Biotechnology?

Senti Biosciences (NASDAQ:SNTI) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Lixte Biotechnology has lower revenue, but higher earnings than Senti Biosciences. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	736.70	-$61.44M	-$1.92	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Lixte Biotechnology's return on equity of -134.91% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Lixte Biotechnology	N/A	-134.91%	-95.61%

In the previous week, Senti Biosciences had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Senti Biosciences and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.84 beat Senti Biosciences' score of 0.23 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 2,014.16%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Senti Biosciences is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Senti Biosciences has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Senti Biosciences beats Lixte Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Enlivex Therapeutics?

Senti Biosciences (NASDAQ:SNTI) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 2,014.16%. Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 5,245.57%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Senti Biosciences has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Enlivex Therapeutics has lower revenue, but higher earnings than Senti Biosciences. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	736.70	-$61.44M	-$1.92	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Enlivex Therapeutics' return on equity of 248.08% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Enlivex Therapeutics	N/A	248.08%	206.39%

In the previous week, Senti Biosciences had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat Senti Biosciences' score of 0.23 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Senti Biosciences beats Enlivex Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.33M	$3.64B	$6.80B	$12.40B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.24	20.61	27.08	24.12
Price / Sales	736.70	304.69	516.47	92.58
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.63	8.04	10.63	6.23
Net Income	-$61.44M	$23.81M	$3.60B	$331.53M
7 Day Performance	-51.11%	-1.31%	-1.08%	-1.30%
1 Month Performance	-49.23%	2.48%	1.28%	-1.40%
1 Year Performance	-76.11%	44.40%	24.71%	18.15%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	3.4072 of 5 stars	$0.47 +9.0%	$10.00 +2,014.2%	-77.8%	$14.33M	$20K	N/A	4
ALDX Aldeyra Therapeutics	3.0614 of 5 stars	$1.93 flat	$5.50 +185.0%	-68.5%	$116.42M	N/A	N/A	10
PMN Promis Neurosciences	3.8373 of 5 stars	$13.66 +6.7%	$24.00 +75.7%	+37.0%	$114.79M	N/A	N/A	5	Analyst Upgrade High Trading Volume
COYA Coya Therapeutics	2.6546 of 5 stars	$4.87 +0.2%	$15.33 +214.9%	-23.6%	$113.89M	$7.95M	N/A	6	Positive News
LIXT Lixte Biotechnology	0.4398 of 5 stars	$7.51 +4.2%	N/A	+85.0%	$112.80M	N/A	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. ALDX, PMN, COYA, LIXT, and ENLV

How does Senti Biosciences compare to Aldeyra Therapeutics?

Summary

How does Senti Biosciences compare to Promis Neurosciences?

Summary

How does Senti Biosciences compare to Coya Therapeutics?

Summary

How does Senti Biosciences compare to Lixte Biotechnology?

Summary

How does Senti Biosciences compare to Enlivex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. ALDX, PMN, COYA, LIXT, and ENLV

How does Senti Biosciences compare to Aldeyra Therapeutics?

Do analysts recommend SNTI or ALDX?

Is SNTI or ALDX more profitable?

Does the media refer more to SNTI or ALDX?

Which has more volatility & risk, SNTI or ALDX?

Which has preferable valuation & earnings, SNTI or ALDX?

Do institutionals & insiders believe in SNTI or ALDX?

Summary

How does Senti Biosciences compare to Promis Neurosciences?

Does the media favor SNTI or PMN?

Do analysts rate SNTI or PMN?

Which has preferable earnings & valuation, SNTI or PMN?

Which has more risk & volatility, SNTI or PMN?

Do insiders & institutionals believe in SNTI or PMN?

Is SNTI or PMN more profitable?

Summary

How does Senti Biosciences compare to Coya Therapeutics?

Which has better valuation and earnings, SNTI or COYA?

Is SNTI or COYA more profitable?

Do institutionals and insiders hold more shares of SNTI or COYA?

Do analysts recommend SNTI or COYA?

Does the media favor SNTI or COYA?

Which has more volatility & risk, SNTI or COYA?

Summary

How does Senti Biosciences compare to Lixte Biotechnology?

Which has stronger earnings & valuation, SNTI or LIXT?

Is SNTI or LIXT more profitable?

Does the media favor SNTI or LIXT?

Do analysts recommend SNTI or LIXT?

Which has more risk & volatility, SNTI or LIXT?

Do institutionals and insiders have more ownership in SNTI or LIXT?

Summary

How does Senti Biosciences compare to Enlivex Therapeutics?

Do analysts prefer SNTI or ENLV?

Which has more risk & volatility, SNTI or ENLV?

Which has better valuation and earnings, SNTI or ENLV?

Is SNTI or ENLV more profitable?

Does the media prefer SNTI or ENLV?

Do insiders and institutionals believe in SNTI or ENLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools